Answers are grounded in this paper and cite their sources.
Review examines serotonergic system alterations in Alzheimer's disease and suggests future research directions.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by several key hallmarks, including the accumulation of amyloid-β (Aβ), neurofibrillary tangles (NFTs), neuroinflammation, and blood-brain barrier (BBB) dysfunction. Similar to other neurodegenerative diseases, AD involves disturbances in neurotransmitter homeostasis. However, the serotonergic system is complex, involving numerous mechanisms and pathways, which complicates the establishment of direct correlations with AD. This review examines the serotonergic system, focusing on alterations in serotonin (5-HT), its transporter, and its receptors in the context of AD, to identify current knowledge gaps and highlight ongoing research directions. It also emphasizes the role of 5-HT in vascular regulation and BBB integrity, and links the gut-brain axis to the serotonergic system.
No takes yet. Share an insight, caveat, or question.
Al-Ghraiybah et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: